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The histologic features of idiopathic forms of focal
segmental glomerulosclerosis (FSGS) were first described
by Theodor Fahr in the Handbuch der speziellen patholo-
gischen Anatomie und Histologie in 1925 [1]. Over the
subsequent eight decades much has been written about the
histologic features and clinical characteristics of patients
with FSGS, but it is only in recent years that attention has
been directed to the incidence and prevalence of the
disorder in various populations. This article will provide
an overview of the epidemiology of FSGS by reviewing
published surveys of renal biopsies, experiences from
clinical registries of children with renal insufficiency, and
data from the U.S. Renal Data Systems (USRDS).
Diagnostic considerations
Primary FSGS can present at any age, and it always causes
proteinuria. It is most commonly diagnosed in patients with
overt nephrotic-range proteinuria, but any proteinuria that is
fixed and persistent over several months (i.e., not orthostatic
or transient proteinuria) may signal underlying FSGS [2, 3].
Since the diagnosis of FSGS depends on obtaining renal
histologic material, the observed incidence and demograph-
ics of FSGS in both children and adults depend on the
population examined and on the indications used for renal
biopsy. The typical findings on renal biopsy in idiopathic
FSGS are described elsewhere in this series of articles.
Incidence and prevalence of FSGS in children
An estimation of the incidence and prevalence of FSGS in
children is hampered by the fact that most children with
nephrotic syndrome (NS), unlike the majority of adults, are
not routinely subjected to renal biopsy. Therefore, preva-
lence and incidence figures are extrapolated from clinical
reports, registries, and renal biopsy materials. Clinical
reports often make the presumptive diagnosis of minimal
change nephrotic syndrome (MCNS) based on steroid
responsiveness [4, 5]. This usually leads to an under-
diagnosis of FSGS because up to 15–20% of FSGS patients
initially respond to steroids [6]. The largest pediatric
registry is that of the North American Pediatric Renal
Transplant Cooperative Study (NAPRTCS), which collects
data not only on transplant patients but also on dialysis and
chronic kidney disease (CKD) patients [6]. Based on results
from nearly 6000 children with CKD, in whom the
estimated glomerular filtration rate (GFR) was less than
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2, it has been shown that FSGS
carries the highest likelihood of progressing to end-stage
renal disease (ESRD), exceeding the risk of hypoplasia,
obstructive uropathy, and reflux nephropathy. According to
NAPRTCS data, nearly 60% of such children with a
diagnosis of FSGS progress to dialysis or transplantation
within 24 months of entry into the registry. However,
because reporting is entirely voluntary and involves mainly
pediatric centers, there is significant underreporting, and
selection bias may exist.
Clinical surveys from North America and the United
Kingdom have reported the incidence of NS to be between
two and four new cases per 100,000 children per year, with
biopsy-confirmed FSGS comprising 15–20% of the total
[5, 7–10]. However, as noted above, many children with
NS do not undergo a diagnostic renal biopsy unless they are
shown to be steroid-resistant. A study from Canada
reported an incidence of FSGS of 0.37 to 0.94 new cases
per 100,000 children per year [5], and similar results were
obtained in the U.S. Midwest [9]. In the NAPRTCS
database, patients with FSGS account for 14.2% of dialysis
patients and for 11.5% of transplant patients; the differences
may reflect a reluctance by some centers to transplant
FSGS patients for fear of disease recurrence. Members of
the Southwest Pediatric Nephrology Study Group (SPNSG)
reported that FSGS was diagnosed in 75 of 1053 (7.1%)
patients with NS who underwent a renal biopsy between
1972 and 1981 [11].
While there is a male preponderance among children
with MCNS, most reports have described no clear gender
difference in patients with FSGS [4, 11, 12], although in the
SPNSG series, all 18 children with FSGS below the age of
3 years were boys [11].
Ethnicity and age appear to play important roles in the
prevalence of FSGS. The NAPRTCS and SPNSG reports
include approximately equal numbers of Caucasian and
African American children with FSGS despite the large
difference in the racial distribution of the underlying
populations [6, 11]. According to the NAPRTCS report,
FSGS is the most common cause of ESRD in African-
American children in that cohort, accounting for 23% of all
pediatric patients with ESRD. In Caucasian children, FSGS
is only the third most common primary disease and is
responsible for approximately 10% of all pediatric patients
with ESRD [5]. In contrast, African-American children with
NS appear to be more likely to have FSGS than MCNS [4,
10, 13]. Whether the frequency of FSGS in Hispanic
children differs from that in Caucasians is unclear [14, 15].
The prevalence of FSGS among all children with NS
who undergo a renal biopsy increases with age. However, it
is not clear if the true population-based incidence of FSGS
is age-dependent. Two thirds of children with NS present
before the age of 6 years, but only a minority of the younger
children exhibit FSGS, whereas FSGS is the most common
histology in the older group. The frequency of FSGS in NS
patients presenting before 6 years of age is less than 10%, but
increases to 20–50% or more in patients presenting in
adolescence [4, 9–11, 16]. The combined effect of age and
ethnicity is responsible for the reported high frequency of
FSGS in kidney biopsies from adolescent African-American
patients with NS [4, 10, 13]; both age and ethnicity are
probably independent risk factors for FSGS histology.
An intriguing recent development has been the apparent
increase in the incidence of FSGS in children [4, 5, 10, 17].
Differences in the ages and ethnicity of the subjects do not
fully explain these findings. Filler et al., for instance,
studied mostly Caucasian children in Canada and found
that the calculated incidence of FSGS increased from 0.37
to 0.94 per 100,000 children per year from the first to the
second half of a 17-year period between 1985 and 2002 [5].
The increase appears to be present mostly in older children
[4]. Similar increases in incidence have not been seen in
other types of NS in children [4, 5]. The cause of the
increased incidence is not known but is unlikely to be due
to genetic factors. The role of environmental pollution has
been proposed but remains hypothetical [18]. Morbid
obesity-associated FSGS has increased in renal biopsy
material [19], but because it remains uncommon, the
current adult and pediatric obesity epidemic probably does
not explain the increase in FSGS.
Incidence and prevalence of FSGS in adults
Several publications suggest that the prevalence of idio-
pathic FSGS in adults may also be increasing [20, 21].
Observations from two metropolitan centers suggest that
FSGS was found in 2.5–4% of native renal biopsies in the
1970s, but in 12.2–18.7% in this decade, making FSGS the
most common diagnosis based on native kidney biopsies.
FSGS becomes less common with advancing age, but it is
still a significant problem in the elderly. In a series of 1368
renal biopsies from patients over 60 years of age, FSGS
was present in 5.4% of those patients with nephrotic
syndrome [20]. These trends in increased numbers of FSGS
cases are observed in both African Americans and
Caucasians and occurred despite stable or falling rates of
other glomerular diseases, such as minimal change disease
and membranous nephropathy [21].
Two large series in adults support the fact that primary FSGS
is a risk factor for developing ESRD. In one report of outcomes
from immunosuppressive therapy in 59 adult patients with
FSGS, 30% of patients developed some level of renal
insufficiency within 5years[22, 23]. Wehrmann and colleagues
reported results from 250 patients with idiopathic FSGS
(average age: 32 years) in which they found an overall 10-
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in idiopathic FSGS can be predicted at the time of diagnosis.
Heavy proteinuria, either at the time of biopsy but particularly
following treatment, portends a poor long-term outcome. Other
features that increase the risk for progressive renal disease
include elevated serum creatinine at the time of diagnosis,
hypertension, age at time of diagnosis, and male gender [22,
24, 25]. The most compelling predictor for progression of
FSGS, however, appears to be the response of proteinuria after
treatment is initiated. One series suggests that if a patient with
primary FSGS fails to respond to initial therapy (most often
steroid-based), the likelihood of renal death is as great as if the
patient received no treatment at all [25]. However, a full
assessment of relative risk will require larger cohorts of
patients with FSGS who received consistent interventions.
The risk of FSGS-related ESRD in adults is also supported
by data published by the USRDS [26]. Documented FSGS
accounts for more than 7000 patients currently receiving
ESRD therapy in the United States, and it is likely that
primary FSGS accounts for at least some of the 25,000
patients with unspecified forms of glomerulonephritis, the
100,000 patients with ESRD attributed to hypertension, and
the 20,000 patients with an unknown cause of ESRD [26].
The USRDS also demonstrates a dramatic increase in the
incidence of ESRD due to FSGS, particularly over the last
decade in the African-American population. In the Caucasian
U.S. population, new-onset ESRD due to FSGS has slowly
increased to a rate of approximately five cases/million
population in 2003. In contrast, the incidence has increased
nearly five-fold in the African-American population since
the early 1980s to 30–40 cases per million population [26].
Familial FSGS
Occasional cases of familial FSGS have long been recog-
nized. In1973 Habibsuggested that12% ofall pediatric cases
of FSGS had an affected sibling [2]. Although most cases of
FSGS are sporadic with unknown pathophysiology, it is now
clear that mutations in structural podocyte-associated pro-
teins account for a portion of familial cases and for at least
some of the sporadic cases. A mutation in the NPHS2 gene,
which encodes the protein podocin, has been linked to
autosomal-recessive steroid-resistant nephrotic syndrome in
children [27]. However, there are large differences between
different ethnic populations. For example, approximately one
third of Israeli-Arab children but none of Israeli-Jewish or
Japanese children with sporadic FSGS were reported to have
NPHS2 mutations [27, 28]. The frequency of NPHS2
mutations in North American children is not known.
Mutations in the a-actinin 4 gene (ACTN4) have been
associated with autosomal-dominant FSGS in adults, a
disease characterized by a variable risk of progression to
ESRD. Most recently, autosomal-dominant FSGS has been
linked to the gene that encodes the transient receptor
potential cation channel, subfamily C, member 6 (TRPC6)
[29]. Although more data are needed, it is likely that
mutations in the known FSGS causative genes account for
only a minority of cases of FSGS in children and adults. A
more complete review of the genetic aspects of FSGS is
provided elsewhere in this series of articles.
Conclusion
It is clear that there is still much to learn about the
epidemiology of idiopathic FSGS. However, there are
encouraging signs that the body of knowledge will be
enhanced in coming years by the various registries and
population-based studies currently underway.
Questions
(Answers appear following the reference list)
1. Which of the following statements is correct?
a. Patients with idiopathic FSGS often present with
microscopic hematuria without proteinuria.
b. All patients with FSGS have nephrotic range
proteinuria.
c. Patients with FSGS have proteinuria of varying
severity.
d. None of the above.
2. Which of the following carries the highest risk for a
patient with FSGS to progress to ESRD?
a. Male gender.
b. Persistent proteinuria after therapy.
c. Hyperlipidemia.
d. Caucasian race.
e. Age.
3. Which of the following is incorrect?
a. Accurate data concerning the outcome of patients
with FSGS is lacking since the disease was first
described only 30 years ago.
b. The incidence of the disease appears to be
decreasing in the last 20 years.
c. Most cases of FSGS can now be linked to specific
gene mutations that disturb podocyte function.
d. All of the above.
e. None of the above.
4. Which of the following is correct?
a. FSGSisa morefrequentcause ofESRDinCaucasian
children than in African-American children.
Pediatr Nephrol (2007) 22:183–186 185b. FSGS is more commonly associated with nephrotic
syndrome in Hispanic children than in white
children.
c. Children with FSGS account for less than 10% of
African-American children who progress to ESRD.
d. All of the above.
e. None of the above.
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